MPSLTD MPS Q3 FY26 results (Oct–Dec 2025) and concall
MPS Limited reported a 'challenging 'holding quarter'' in Q3 FY26 with a minor dip in revenue to INR 182.5 crores, while 9M revenue grew to INR 563.2 crores. Despite this, the company maintained a healthy Q3 EBITDA margin of 31.6%. Education Solutions emerged as a strong performer, growing over 38% in 9M FY26, while Research Solutions remained a stable anchor. Corporate Learning experienced a significant pullback, prompting a strategic realignment. The company also announced the acquisition of Unbound Medicine for USD 16.5 million, a move expected to drive growth in the medical and nursing eco
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 20.0%, net profit down 13.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 87 | 90 | 94 | 100 | 111 +28% | 108 +20% |
| EBITDA | 35 | 34 | 35 | 34 | 44 +26% | 41 +21% |
| Net profit | 27 | 29 | 27 | 29 | 30 +11% | 25 −14% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
